Skip to content

HypnoTreat: Reduction of oxidative stress, increased inflammatory processes and improvement of mitochondrial function through hypnosis

HypnoTreat: Reduction of oxidative stress, increased inflammatory processes and improvement of mitochondrial function through hypnosis - HypnoTreat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00027356
Enrollment
40
Registered
2021-12-07
Start date
2020-02-19
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic stress

Interventions

Group 1: relaxation hypnosis Group 2: documentary

Sponsors

Institut für Psychologie und Pädagogik, Universität Ulm
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age at least 18 years; sufficient knowledge of German; good hypnotizability of the subjects (score HGSHS:A = 6; BER: medium to high scores, i.e. 24-48); ability of the subject to give consent; signed consent form. Healthy or health stable subjects; High subjective stress level.

Exclusion criteria

Exclusion criteria: Excludes individuals with acute and past neuropsychiatric disorders or diseases, including Parkinson's disease, Alzheimer's disease, schizophrenia, and substance abuse. Also, individuals with known anemia, immune disorders, autoimmune diseases, acute cancer and diabetes mellitus, and known chronic viral infections such as HIV and hepatitis. Also excluded are individuals who are taking medications with known influence on the immune system, for example immunosuppressants, cytostatics or comparable relevant substance classes, or who have been vaccinated in the past 7 days prior to study inclusion. The intake of iron or vitamin E supplements in a dose of more than 800 IU per day is also an exclusion criterion. Further exclusion criteria are inadequate German language skills and acute mental illnesses

Design outcomes

Primary

MeasureTime frame
Primary outcomes will be measured using participants' whole blood and immune cells at pre- and post-intervention ATP-turnover-related respiration, uncoupled respiration, and routine respiration will be measured on immune cells using high-resolution respirometry. Mitochondrial density of immune cells will be determined spectrophotometrically.

Secondary

MeasureTime frame
Secondary outcomes will include differential blood work and inflammatory parameters (CRP, IL-1beta, IL-6,TNF-alpha) and psychological standardized questionnaires (anxiety, affect, stress).

Countries

Germany

Contacts

Public ContactSarah Karrasch

Institut für Psychologie und Pädagogik, Universität Ulm

sarah.karrasch@uni-ulm.de+49731-5026597

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 10, 2026